BP therapy is beneficial in MP-associated osteoporosis and may improve fasting plasma glucose, HbA1c, and insulin indices in postmenopausal women; however, the treatment compliance is still reduced, and efficacy may be genetically influenced by non-responders to therapy. The gene discussed is INS; the disease is osteoporosis.